Home » Stocks » ALLK

Allakos Inc. (ALLK)

Stock Price: $129.40 USD 2.36 (1.86%)
Updated Jan 20, 2021 1:46 PM EST - Market open
Market Cap 6.67B
Revenue (ttm) n/a
Net Income (ttm) -133.82M
Shares Out 48.95M
EPS (ttm) -2.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $129.40
Previous Close $127.04
Change ($) 2.36
Change (%) 1.86%
Day's Open 128.32
Day's Range 128.32 - 133.51
Day's Volume 125,832
52-Week Range 44.04 - 152.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 weeks ago

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

GlobeNewsWire - 4 weeks ago

REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-relat...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell rela...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and m...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell rela...

GlobeNewsWire - 2 months ago

-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression support ing once monthly dosing -- -- Management to host conference ca...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-relat...

GlobeNewsWire - 5 months ago

REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-re...

GlobeNewsWire - 7 months ago

-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis --  -- Top-line safety and efficacy results from both studies expec...

Zacks Investment Research - 8 months ago

Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Allakos Inc (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 8 months ago

REDWOOD CITY, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and m...

GlobeNewsWire - 8 months ago

-- Antolimab treatment provided durable symptom improvement and blood and tissue eosinophil depletion -- -- Symptomatic benefit increased with duration of antolimab treatment --

GlobeNewsWire - 9 months ago

-- Antolimab (AK002) reduced gastrointestinal symptoms by 64 percent in patients with mast cell gastrointestinal disease -- -- Management to host conference call and webcast today at 5:00 p...

GlobeNewsWire - 9 months ago

-- Management to host conference call and webcast today at 5:00 pm ET -- REDWOOD CITY, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company develo...

Seeking Alpha - 1 year ago

Allakos Does It Again; bluebird And Sunesis Data: The Good, Bad And Ugly Of Biopharma

Market Watch - 1 year ago

Shares of Allakos Inc. rallied 37% in afternoon trading, to a record high.

GlobeNewsWire - 1 year ago

REDWOOD CITY, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, ...

The Motley Fool - 1 year ago

Find out why these new healthcare stocks keep climbing, while most of their peers have underwhelmed.

Other stocks mentioned: GH, TWST
The Motley Fool - 1 year ago

Investors were enthused about this biotech's positive phase 2 results for its lead investigational therapy, AK002.

24/7 Wall Street - 1 year ago

Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages.

Other stocks mentioned: VRTX, BHVN, FOLD, JAZZ
Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Allakos.

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for August 9th

Other stocks mentioned: BURBY, CSV, GAIA

About ALLK

Allakos operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.

Industry
Biotechnology
IPO Date
Jul 19, 2018
CEO
Robert Alexander
Employees
114
Stock Exchange
NASDAQ
Ticker Symbol
ALLK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Allakos stock is "Buy." The 12-month stock price forecast is 122.00, which is a decrease of -5.72% from the latest price.

Price Target
$122.00
(-5.72% downside)
Analyst Consensus: Buy